Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed tha...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/2a6790e7eddf4f60855715ed7fd73757
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2a6790e7eddf4f60855715ed7fd73757
record_format dspace
spelling oai:doaj.org-article:2a6790e7eddf4f60855715ed7fd737572021-12-02T16:14:09ZImpact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib10.1038/s41598-021-93794-52045-2322https://doaj.org/article/2a6790e7eddf4f60855715ed7fd737572021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93794-5https://doaj.org/toc/2045-2322Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed that mALBI grade 2b/3 and Child–Pugh class B/C were significantly associated with survival [hazard ratio (HR), 2.471; 95% confidence interval (CI), 1.944–3.141 and HR, 2.178; 95%CI, 1.591–2.982]. In patients with a Child–Pugh score of 5, multivariate analysis showed that mALBI grade 2b/3 was independently associated with survival (HR, 1.814; 95%CI, 1.083–3.037). Conversely, among patients with mALBI grade 1/2a, there was no difference in survival between those with a Child–Pugh class of 5 or 6 (p = 0.735). Time-dependent receiver operating characteristic analysis showed that the ALBI score predicted survival better than the Child–Pugh score. The optimal cut-off value of the ALBI score for predicting survival was nearly the same as the value separating mALBI grades 2a and 2b. In conclusion, the mALBI grade was a better predictor of survival than the Child–Pugh classification in patients with unresectable HCC who received lenvatinib therapy.Toshifumi TadaTakashi KumadaAtsushi HiraokaMasanori AtsukawaMasashi HirookaKunihiko TsujiToru IshikawaKoichi TakaguchiKazuya KariyamaEi ItobayashiKazuto TajiriNoritomo ShimadaHiroshi ShibataHironori OchiSatoshi YasudaHidenori ToyodaShinya FukunishiHideko OhamaKazuhito KawataJoji TaniShinichiro NakamuraKazuhiro NousoAkemi TsutsuiTakuya NaganoTanaka TakaakiNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiKouji JokoYohei KoizumiYoichi HiasaReal-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)Nature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Toshifumi Tada
Takashi Kumada
Atsushi Hiraoka
Masanori Atsukawa
Masashi Hirooka
Kunihiko Tsuji
Toru Ishikawa
Koichi Takaguchi
Kazuya Kariyama
Ei Itobayashi
Kazuto Tajiri
Noritomo Shimada
Hiroshi Shibata
Hironori Ochi
Satoshi Yasuda
Hidenori Toyoda
Shinya Fukunishi
Hideko Ohama
Kazuhito Kawata
Joji Tani
Shinichiro Nakamura
Kazuhiro Nouso
Akemi Tsutsui
Takuya Nagano
Tanaka Takaaki
Norio Itokawa
Tomomi Okubo
Taeang Arai
Michitaka Imai
Kouji Joko
Yohei Koizumi
Yoichi Hiasa
Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
description Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed that mALBI grade 2b/3 and Child–Pugh class B/C were significantly associated with survival [hazard ratio (HR), 2.471; 95% confidence interval (CI), 1.944–3.141 and HR, 2.178; 95%CI, 1.591–2.982]. In patients with a Child–Pugh score of 5, multivariate analysis showed that mALBI grade 2b/3 was independently associated with survival (HR, 1.814; 95%CI, 1.083–3.037). Conversely, among patients with mALBI grade 1/2a, there was no difference in survival between those with a Child–Pugh class of 5 or 6 (p = 0.735). Time-dependent receiver operating characteristic analysis showed that the ALBI score predicted survival better than the Child–Pugh score. The optimal cut-off value of the ALBI score for predicting survival was nearly the same as the value separating mALBI grades 2a and 2b. In conclusion, the mALBI grade was a better predictor of survival than the Child–Pugh classification in patients with unresectable HCC who received lenvatinib therapy.
format article
author Toshifumi Tada
Takashi Kumada
Atsushi Hiraoka
Masanori Atsukawa
Masashi Hirooka
Kunihiko Tsuji
Toru Ishikawa
Koichi Takaguchi
Kazuya Kariyama
Ei Itobayashi
Kazuto Tajiri
Noritomo Shimada
Hiroshi Shibata
Hironori Ochi
Satoshi Yasuda
Hidenori Toyoda
Shinya Fukunishi
Hideko Ohama
Kazuhito Kawata
Joji Tani
Shinichiro Nakamura
Kazuhiro Nouso
Akemi Tsutsui
Takuya Nagano
Tanaka Takaaki
Norio Itokawa
Tomomi Okubo
Taeang Arai
Michitaka Imai
Kouji Joko
Yohei Koizumi
Yoichi Hiasa
Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
author_facet Toshifumi Tada
Takashi Kumada
Atsushi Hiraoka
Masanori Atsukawa
Masashi Hirooka
Kunihiko Tsuji
Toru Ishikawa
Koichi Takaguchi
Kazuya Kariyama
Ei Itobayashi
Kazuto Tajiri
Noritomo Shimada
Hiroshi Shibata
Hironori Ochi
Satoshi Yasuda
Hidenori Toyoda
Shinya Fukunishi
Hideko Ohama
Kazuhito Kawata
Joji Tani
Shinichiro Nakamura
Kazuhiro Nouso
Akemi Tsutsui
Takuya Nagano
Tanaka Takaaki
Norio Itokawa
Tomomi Okubo
Taeang Arai
Michitaka Imai
Kouji Joko
Yohei Koizumi
Yoichi Hiasa
Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
author_sort Toshifumi Tada
title Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
title_short Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
title_full Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
title_fullStr Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
title_full_unstemmed Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
title_sort impact of modified albumin–bilirubin grade on survival in patients with hcc who received lenvatinib
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/2a6790e7eddf4f60855715ed7fd73757
work_keys_str_mv AT toshifumitada impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT takashikumada impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT atsushihiraoka impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT masanoriatsukawa impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT masashihirooka impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT kunihikotsuji impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT toruishikawa impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT koichitakaguchi impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT kazuyakariyama impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT eiitobayashi impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT kazutotajiri impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT noritomoshimada impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT hiroshishibata impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT hironoriochi impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT satoshiyasuda impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT hidenoritoyoda impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT shinyafukunishi impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT hidekoohama impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT kazuhitokawata impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT jojitani impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT shinichironakamura impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT kazuhironouso impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT akemitsutsui impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT takuyanagano impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT tanakatakaaki impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT norioitokawa impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT tomomiokubo impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT taeangarai impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT michitakaimai impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT koujijoko impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT yoheikoizumi impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT yoichihiasa impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
AT reallifepracticeexpertsforhccrelpecstudygroupandthehcc48grouphepatocellularcarcinomaexpertsfrom48clinicsinjapan impactofmodifiedalbuminbilirubingradeonsurvivalinpatientswithhccwhoreceivedlenvatinib
_version_ 1718384340189052928

Ejemplares similares